Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 17

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 17
---
2021 Incentive Award Plan as of June 30, 2025; • 1,051,390 shares of Class A common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan as of June 30, 2025; • 382,000 shares of Class A common stock reserved for future issuance under our 2025 Employment Inducement Award Plan as of June 30, 2025; and • 5,251,349 outstanding shares of Class A common stock, 1,077,764 shares of Class A common stock issuable upon exercise of outstanding pre-funded warrants with an exercise price of $0.001, and 2,848,096 shares of Class A common stock issuable upon exercise of outstanding purchase warrants with an exercise price of $5.50 per share, in each case, issued on August 26, 2025 pursuant to the terms of that certain securities purchase agreement, dated as of August 21, 2025, by and among us and the purchasers party thereto. The foregoing table does not give effect to the exercise of any options outstanding as of June 30, 2025. To the extent options or warrants are exercised, there may be further dilution to new investors.

S-13

TABLE OF CONTENTS

### CONCURRENT PRIVATE PLACEMENT
On September 24, 2025, we entered into a securities purchase agreement (referred to herein as the Purchase Agreement) with Aventis Inc. (referred to herein as the Investor), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which we, in a private placement transaction, or the Private Placement, agreed to issue and sell to the Investor $25.0 million of shares of our Class A common stock, or the Class A Shares, or in certain circumstances in lieu of Class A Shares, shares of our non-voting Class B common stock, or the Class B Shares, subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A common stock by us that results in gross proceeds to us of at least $75.0 million and the pricing of which is publicly announced in a press release issued by us on or before September 26, 2025 (referred to herein as a qualified public offering). The price per share will be the price per share of Class A common stock to the public in the qualified public offering as set forth on the cover of the definitive prospectus related to the qualified